Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cogent Biosciences, Inc.

7.63
-0.0450-0.59%
Volume:105.89K
Turnover:803.33K
Market Cap:868.11M
PE:-3.93
High:7.71
Open:7.55
Low:7.50
Close:7.67
Loading ...

Cogent Biosciences Reports Updated Results From Trial of Bezuclastinib

MT Newswires Live
·
09 Dec 2024

Cogent Biosciences announces updates results from SUMMIT

TIPRANKS
·
09 Dec 2024

BRIEF-Cogent Biosciences Updated Clinical Results From Open Label Extension Portion Of Summit Trial

Reuters
·
09 Dec 2024

Cogent Biosciences: Updated Clinical Results From Open Label Extension Portion of Summit Trial

THOMSON REUTERS
·
09 Dec 2024

Cogent Biosciences Inc: Top-Line Results NOW Expected in July 2025

THOMSON REUTERS
·
09 Dec 2024

Cogent Biosciences: 56% Mean Improvement in Total Symptom Score at 24 Weeks With 76% of Patients Achieving at Least a 50% Reduction in Tss

THOMSON REUTERS
·
09 Dec 2024

Cogent Biosciences Price Target Maintained With a $15.00/Share by Needham

Dow Jones
·
09 Dec 2024

Cogent Biosciences announces updated data from ongoing Phase 2 APEX trial

TIPRANKS
·
09 Dec 2024

Cogent Biosciences Is Maintained at Overweight by JP Morgan

Dow Jones
·
15 Nov 2024

Cogent Biosciences Inc : Needham Cuts Target Price to $15 From $16

THOMSON REUTERS
·
13 Nov 2024

Cogent Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
12 Nov 2024

BRIEF-Cogent Biosciences Q3 EPS USD -0.64

Reuters
·
12 Nov 2024

Cogent Biosciences Inc: Strong Cash Position of $346 Mln Sufficient to Fund Operations Into Late 2026

THOMSON REUTERS
·
12 Nov 2024

Cogent Biosciences Inc: Top-Line Results From Registration-Directed Summit, Peak and Apex Trials Expected in 2025

THOMSON REUTERS
·
12 Nov 2024

Cogent selloff on ‘old news’ is ‘unwarranted,’ says Citi

TIPRANKS
·
06 Nov 2024

Cogent data has positive read-through to Blueprint, says Barclays

TIPRANKS
·
06 Nov 2024